UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health

Journal of hepatology, 2012-07, Vol.57 (1), p.133-140

2012

Link zum Volltext

Verfügbarkeit prüfen

Suicidal attempt with eliglustat overdose

JIMD reports, 2023-01, Vol.64 (1), p.23-26

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical trial: A novel high‐dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500‐mg suppository thrice daily in active ulcerative proctitis

Inflammatory bowel diseases, 2010-11, Vol.16 (11), p.1947-1956

2010

Link zum Volltext

Verfügbarkeit prüfen

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

Clinical pharmacokinetics, 2003, Vol.42 (3), p.283-292

2003

Link zum Volltext

Verfügbarkeit prüfen

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

Gut, 2010-06, Vol.59 (6), p.752-759

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction

Clinical pharmacology and therapeutics, 1998-05, Vol.63 (5), p.552-560

1998

Link zum Volltext

Verfügbarkeit prüfen

Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

British journal of clinical pharmacology, 1999-09, Vol.48 (3), p.438-444

1999

Link zum Volltext

Verfügbarkeit prüfen

Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis

Liver international, 2006-04, Vol.26 (3), p.285-290

2006

Link zum Volltext

Verfügbarkeit prüfen

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease

Journal of Crohn's and colitis, 2017-04, Vol.11 (4), p.390-399

2017

Link zum Volltext

Verfügbarkeit prüfen

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study

Digestive and liver disease, 2015-02, Vol.47 (2), p.144-150

2015

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP1B1, OATP1B3, OATP2B1 and NTCP

Basic & clinical pharmacology & toxicology, 2012-08, Vol.111 (2), p.81-86

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

Hepatology (Baltimore, Md.), 2003-07, Vol.38 (1), p.196-202

2003

Link zum Volltext

Verfügbarkeit prüfen

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2011-02, Vol.140 (2), p.425-434.e1

2011

Link zum Volltext

Verfügbarkeit prüfen

Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes

Digestion, 2013-01, Vol.87 (2), p.110-117

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial

United European gastroenterology journal, 2018-02, Vol.6 (1), p.138-147

2018

Link zum Volltext

Verfügbarkeit prüfen

Chronopharmacology of intravenous and oral modified release verapamil

British journal of clinical pharmacology, 1999-04, Vol.47 (4), p.413-419

1999

Link zum Volltext

Verfügbarkeit prüfen

Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P‐glycoprotein

Inflammatory bowel diseases, 2004-09, Vol.10 (5), p.578-583

2004

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP 1B1, OATP 1B3, OATP 2B1 and NTCP

Basic & clinical pharmacology & toxicology, 2012-08, Vol.111 (2), p.81-86

2012

Link zum Volltext

Verfügbarkeit prüfen

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

Journal of Crohn's and colitis, 2011-04, Vol.5 (2), p.129-138

2011

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to: “Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health” [J Hepatol 2012;57:133–140]

Journal of hepatology, 2014-03, Vol.60 (3), p.684-684

2014

Link zum Volltext

Verfügbarkeit prüfen

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels

Inflammatory bowel diseases, 2013-03, Vol.19 (3), p.590-598

2013

Link zum Volltext

Verfügbarkeit prüfen

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine

Therapeutic drug monitoring, 2007-02, Vol.29 (1), p.1

2007

Link zum Volltext

Verfügbarkeit prüfen

1052 Daily Mesalamine Fails to Prevent Recurrent Diverticulitis in a Large Placebo Controlled Multicenter Trial

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-187-S-187

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(45)
Japanisch
(11)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Humans
(31)
Life Sciences & Biomedicine
(31)
Male
(27)
Female
(25)
Adult
(24)
Gastroenterology & Hepatology
(18)
Middle Aged
(16)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Aged
(13)
Double-Blind Method
(11)
Pharmacology & Pharmacy
(11)
Pharmacology. Drug Treatments
(11)
Administration, Oral
(8)
Area Under Curve
(8)
Gastroenterology And Hepatology
(8)
Treatment Outcome
(8)
Budesonide - Pharmacokinetics
(7)
Anti-Inflammatory Agents - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health

Suicidal attempt with eliglustat overdose

Clinical trial: A novel high‐dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500‐mg suppository thrice daily in active ulcerative proctitis

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial

Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction

Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study

Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP1B1, OATP1B3, OATP2B1 and NTCP

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial

Chronopharmacology of intravenous and oral modified release verapamil

Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P‐glycoprotein

Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP 1B1, OATP 1B3, OATP 2B1 and NTCP

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

Corrigendum to: “Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health” [J Hepatol 2012;57:133–140]

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine

1052 Daily Mesalamine Fails to Prevent Recurrent Diverticulitis in a Large Placebo Controlled Multicenter Trial

Suchergebnisse filtern